Product Elements:
Diphenoxylate hydrochloride and atropine sulfate diphenoxylate hydrochloride and atropine sulfate diphenoxylate hydrochloride diphenoxylate atropine sulfate atropine acacia starch, corn magnesium stearate sorbitol talc sucrose searle;61
Indications and Usage:
Indications and usage diphenoxylate hydrochloride is effective as adjunctive therapy in the management of diarrhea.
Warnings:
Warnings diphenoxylate hydrochloride is not an innocuous drug and dosage recommendations should be strictly adhered to, especially in children. diphenoxylate hydrochloride is not recommended for children under 2 years of age. overdosage may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death (see overdosage). therefore, keep this medication out of the reach of children. the use of diphenoxylate hydrochloride should be accompanied by appropriate fluid and electrolyte therapy, when indicated. if severe dehydration or electrolyte imbalance is present, diphenoxylate hydrochloride should be withheld until appropriate corrective therapy has been initiated. drug-induced inhibition of peristalsis may result in fluid retention in the intestine, which may further aggravate dehydration and electrolyte imbalance. diphenoxylate hydrochloride should be used with special caution in young children because this age group may be predisposed to delayed di
Read more...phenoxylate toxicity and because of the greater variability of response in this age group. antiperistaltic agents may prolong and/or worsen diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic e. coli, salmonella, shigella), and pseudomembranous enterocolitis associated with broad-spectrum antibiotics. antiperistaltic agents should not be used in these conditions. in some patients with acute ulcerative colitis, agents that inhibit intestinal motility or prolong intestinal transit time have been reported to induce toxic megacolon. consequently, patients with acute ulcerative colitis should be carefully observed and diphenoxylate hydrochloride therapy should be discontinued promptly if abdominal distention occurs or if other untoward symptoms develop. since the chemical structure of diphenoxylate hydrochloride is similar to that of meperidine hydrochloride, the concurrent use of diphenoxylate hydrochloride with monoamine oxidase (mao) inhibitors may, in theory, precipitate hypertensive crisis. diphenoxylate hydrochloride should be used with extreme caution in patients with advanced hepatorenal disease and in all patients with abnormal liver function since hepatic coma may be precipitated. diphenoxylate hydrochloride may potentiate the action of barbiturates, tranquilizers, and alcohol. therefore, the patient should be closely observed when any of these are used concomitantly.
Dosage and Administration:
Dosage and administration do not exceed recommended dosage. adults the recommended initial dosage is two diphenoxylate hydrochloride tablets four times daily . most patients will require this dosage until initial control has been achieved, after which the dosage may be reduced to meet individual requirements. control may often be maintained with as little as 5 mg (two tablets) daily. clinical improvement of acute diarrhea is usually observed within 48 hours. if clinical improvement of chronic diarrhea after treatment with a maximum daily dose of 20 mg of diphenoxylate hydrochloride is not observed within 10 days, symptoms are unlikely to be controlled by further administration. children diphenoxylate hydrochloride is not recommended in children under 2 years of age and should be used with special caution in young children (see warnings and precautions). the nutritional status and degree of dehydration must be considered. do not use diphenoxylate hydrochloride tablets for children under
Read more... 13 years of age . keep this and all medications out of the reach of children.
Contraindications:
Contraindications diphenoxylate hydrochloride is contraindicated in patients with: known hypersensitivity to diphenoxylate or atropine. obstructive jaundice. diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria.
Adverse Reactions:
Adverse reactions at therapeutic doses, the following have been reported; they are listed in decreasing order of severity, but not of frequency: nervous system: numbness of extremities, euphoria, depression, malaise/lethargy, confusion, sedation/drowsiness, dizziness, restlessness, headache. allergic: anaphylaxis, angioneurotic edema, urticaria, swelling of the gums, pruritus. gastrointestinal system: toxic megacolon, paralytic ileus, pancreatitis, vomiting, nausea, anorexia, abdominal discomfort. the following atropine sulfate effects are listed in decreasing order of severity, but not of frequency: hyperthermia, tachycardia, urinary retention, flushing, dryness of the skin and mucous membranes. these effects may occur, especially in children. this medication should be kept in a child-resistant container and out of the reach of children since an overdosage may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death.
Overdosage:
Overdosage recommended dosage schedules should be strictly followed. this medication should be kept in a child-resistant container and out of the reach of children, since an overdosage may result in severe, even fatal, respiratory depression. diagnosis initial signs of overdosage may include dryness of the skin and mucous membranes, mydriasis, restlessness, flushing, hyperthermia, and tachycardia followed by lethargy or coma, hypotonic reflexes, nystagmus, pinpoint pupils, and respiratory depression. respiratory depression may be evidenced as late as 30 hours after ingestion and may recur despite an initial response to narcotic antagonists. treat all possible diphenoxylate hydrochloride overdosages as serious and maintain medical observation for at least 48 hours, preferably under continuous hospital care. treatment in the event of overdose, induction of vomiting, gastric lavage, establishment of a patent airway, and possibly mechanically assisted respiration are advised. in vitro and animal studies indicate that activated charcoal may significantly decrease the bioavailability of diphenoxylate. in noncomatose patients, a slurry of 100 g of activated charcoal can be administered immediately after the induction of vomiting or gastric lavage. a pure narcotic antagonist (e.g., naloxone) should be used in the treatment of respiratory depression caused by diphenoxylate hydrochloride. when a narcotic antagonist is administered intravenously, the onset of action is generally apparent within two minutes. it may also be administered subcutaneously or intramuscularly, providing a slightly less rapid onset of action but a more prolonged effect. to counteract respiratory depression caused by diphenoxylate hydrochloride overdosage, the following dosage schedule for the narcotic antagonist naloxone hydrochloride should be followed: adult dosage an initial dose of 0.4 mg to 2 mg of naloxone hydrochloride may be administered intravenously. if the desired degree of counteraction and improvement in respiratory functions is not obtained, it may be repeated at 2- to 3-minute intervals. if no response is observed after 10 mg of naloxone hydrochloride has been administered, the diagnosis of narcotic-induced or partial narcotic-induced toxicity should be questioned. intramuscular or subcutaneous administration may be necessary if the intravenous route is not available. children the usual initial dose in children is 0.01 mg/kg body weight given i.v. if this dose does not result in the desired degree of clinical improvement, a subsequent dose of 0.1 mg/kg body weight may be administered. if an i.v. route of administration is not available, naloxone hydrochloride may be administered i.m. or s.c. in divided doses. if necessary, naloxone hydrochloride can be diluted with sterile water for injection. following initial improvement of respiratory function, repeated doses of naloxone hydrochloride may be required to counteract recurrent respiratory depression. supplemental intramuscular doses of naloxone hydrochloride may be utilized to produce a longer-lasting effect. since the duration of action of diphenoxylate hydrochloride is longer than that of naloxone hydrochloride, improvement of respiration following administration may be followed by recurrent respiratory depression. consequently, continuous observation is necessary until the effect of diphenoxylate hydrochloride on respiration has passed. this effect may persist for many hours. the period of observation should extend over at least 48 hours, preferably under continuous hospital care. although signs of overdosage and respiratory depression may not be evident soon after ingestion of diphenoxylate hydrochloride, respiratory depression may occur from 12 to 30 hours later.
Description:
Description each diphenoxylate hydrochloride and atropine sulfate tablet contains: diphenoxylate hydrochloride 2.5 mg atropine sulfate 0.025 mg diphenoxylate hydrochloride, an antidiarrheal, is ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride and has the following structural formula: [chemical structure] atropine sulfate, an anticholinergic, is endo-(±)-α-(hydroxymethyl) benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1] oct-3-yl ester sulfate (2:1) (salt) monohydrate and has the following structural formula: [chemical structure] a subtherapeutic amount of atropine sulfate is present to discourage deliberate overdosage. inactive ingredients of diphenoxylate hydrochloride tablets include acacia, corn starch, magnesium stearate, sorbitol, sucrose, and talc.
Clinical Pharmacology:
Clinical pharmacology diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood. after a 5-mg oral dose of carbon-14 labeled diphenoxylate hydrochloride in ethanolic solution was given to three healthy volunteers, an average of 14% of the drug plus its metabolites was excreted in the urine and 49% in the feces over a four-day period. urinary excretion of the unmetabolized drug constituted less than 1% of the dose, and diphenoxylic acid plus its glucuronide conjugate constituted about 6% of the dose. in a 16-subject crossover bioavailability study, a linear relationship in the dose range of 2.5 to 10 mg was found between the dose of diphenoxylate hydrochloride (given as diphenoxylate hydrochloride liquid) and the peak plasma concentration, the area under the plasma concentration-time curve, and the amount of diphenoxylic acid excreted in the urine. in the same stud
Read more...y the bioavailability of the tablet compared with an equal dose of the liquid was approximately 90%. the average peak plasma concentration of diphenoxylic acid following ingestion of four 2.5-mg tablets was 163 ng/ml at about 2 hours, and the elimination half-life of diphenoxylic acid was approximately 12 to 14 hours. in dogs, diphenoxylate hydrochloride has a direct effect on circular smooth muscle of the bowel that conceivably results in segmentation and prolongation of gastrointestinal transit time. the clinical antidiarrheal action of diphenoxylate hydrochloride may thus be a consequence of enhanced segmentation that allows increased contact of the intraluminal contents with the intestinal mucosa.
How Supplied:
How supplied tablets â round, white, with searle debossed on one side and 61 on the other side and containing 2.5 mg of diphenoxylate hydrochloride and 0.025 mg of atropine sulfate, supplied as: ndc number size 59762-1061-1 bottle of 100 59762-1061-2 bottle of 1000
Package Label Principal Display Panel:
Principal display panel - 2.5 mg/0.025 mg tablet bottle label diphenoxylate/atropine